Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 8/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | APEX1 | P27695 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1032002 | 0.90 | MAPK1 (0.77) | HPGDALDH1A1KDM4EMAPK1HSD17B10 | |
| SCHEMBL15686618 | 0.87 | KMT2A (0.70) | HPGDALDH1A1KDM4EMAPK1SMN1; SMN2 | |
| SCHEMBL30498656 | 0.87 | HPGD (0.64) | HPGDALDH1A1KDM4EMAPK1HSD17B10 | |
| SCHEMBL19358930 | 0.87 | CA12 (0.62) | HPGDALDH1A1KDM4EMAPK1HSD17B10 | |
| SCHEMBL7823453 | 0.85 | APEX1 (0.84) | HPGDALDH1A1KDM4EHSD17B10SMN1; SMN2 | |
| SCHEMBL17339617 | 0.84 | MAPK1 (0.65) | HPGDALDH1A1KDM4EMAPK1HSD17B10 | |
| SCHEMBL4569297 | 0.84 | HPGD (0.69) | HPGDALDH1A1MAPK1SMN1; SMN2TP53 | |
| SCHEMBL13161957 | 0.84 | MAPK1 (1.00) | HPGDALDH1A1KDM4EMAPK1HSD17B10 | |
| SCHEMBL15686093 | 0.84 | HPGD (0.68) | HPGDALDH1A1KDM4EHSD17B10SMN1; SMN2 | |
| SCHEMBL15686111 | 0.84 | ALDH1A1 (0.68) | HPGDALDH1A1KDM4EHSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264568-A1 | SUBSTITUTED TRIAZOLOPYRIDINES HAVING ACTIVITY AS MPS-1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-15 | — | — | US | disclosed |
| US-20140120087-A1 | TRIAZOLOPYRIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-01 | — | — | US | disclosed |
| EP-1572660-B1 | ISOQUINOLINONE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | X CEPTOR THERAPEUTICS INC (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20080132521-A1 | Isoquinolinone Derivatives and Their Use As Therapeutic Agents | EXELIXIS, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-7265131-B2 | Isoquinolinone derivatives and their use as therapeutic agents | EXELIXIS, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-20040204447-A1 | Isoquinolinone derivatives and their use as therapeutic agents | X-CEPTOR THERAPEUTICS INC. | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140120087-A1 | TRIAZOLOPYRIDINES | QDPR, TBXA2R, KCNJ11 | HPGD 922/4885ALDH1A1 1037/4885KDM4E 3950/4885 |
| US-20160264568-A1 | SUBSTITUTED TRIAZOLOPYRIDINES HAVING ACTIVITY AS MPS-1 INHIBITORS | CMA1, TPP1, TPSAB1 | HPGD 2745/4885ALDH1A1 1586/4885KDM4E 4498/4885 |
| US-20080132521-A1 | Isoquinolinone Derivatives and Their Use As Therapeutic Agents | NR1H2, NR1H3, NR1I2 | HPGD 344/4885ALDH1A1 601/4885KDM4E 3727/4885 |
| US-20040204447-A1 | Isoquinolinone derivatives and their use as therapeutic agents | NR1H2, NR1I2, NR1H3 | HPGD 391/4885ALDH1A1 415/4885KDM4E 4119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.